Form 4: Recursion Pharmaceuticals CFO Michael Secora Executes Stock Option Plan, Sells Shares

Michael Secora, CFO of Recursion Pharmaceuticals, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, executed transactions involving Class A Common Stock on April 16 and April 17, 2024.
• These transactions involved the exercise of stock options at a price of $2.22 and the subsequent sale of shares at weighted average prices of $7.6663 and $7.583, respectively.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on March 1, 2023.
• Secora's beneficial ownership of Class A Common Stock following these transactions is 1,231,055 shares.
• He also holds derivative securities in the form of stock options with various exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There's no inherent positive or negative signal.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, potentially leading to short-term price fluctuations.

Key Dates